1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Zhongzhi Pharmaceutical Holdings Limited

Zhongzhi Pharmaceutical Holdings Limited

3737.HK
Zhongzhi Pharmaceutical Holdings LimitedHK flagHong Kong Stock Exchange
0.69
HKD
- -
- -
582.18MMarket Cap
Zhongzhi Pharmaceutical Holdings Limited
3737.HK
(Hong Kong Stock Exchange)

Recent

price

0.69

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
FRC
0.99
0.99
0.92
1.18
1.37
1.61
1.94
2.09
2.16
2.42
2.62
Revenue per Share
0.14
0.12
0.07
0.09
0.1
0.14
0.17
0.06
0.13
0.19
0.11
Basic EPS, GAAP
0.17
0.04
-0.08
- -
- -
0.11
-0.04
-0.01
0.23
-0.08
0.05
Free Cash Flow per Basic Share
0.16
0.04
0.04
0.02
0.07
0.07
0.08
- -
- -
0.14
0.03
Dividend per Share
0.13
0.16
0.21
0.29
0.38
0.51
0.67
0.01
0.79
0.97
1.07
Book Value per Share
0.2
0.81
0.69
0.8
0.82
0.87
0.93
1.02
1.17
1.22
1.31
Tangible Book Value per Share
600
694
794
799
833
833
829
837
847
847
845
Basic Weighted Avg Shares
596
688
730
945
1,142
1,342
1,604
1,746
1,826
2,050
2,215
Sales/Revenue/Turnover
19.31
17.47
8.18
9.16
8.17
10.77
9.94
5.85
7.07
9.7
7.04
Operating Margin (%)
12
16
22
23
26
64
100
85
96
102
111
Depreciation Expense
87
81
54
70
85
115
139
52
106
163
95
Net Income, GAAP
24.49
20.41
22.1
22.05
16.45
26.45
17.1
15.28
18.17
20.93
34.55
Effective Tax Rate (%)
14.56
11.71
7.37
7.42
7.45
8.55
8.64
2.98
5.83
7.94
4.3
Profit Margin (%)
27
451
362
428
413
416
398
357
360
266
283
Working Capital
- -
- -
- -
- -
- -
64
73
81
95
99
107
LT Debt
121
563
568
668
707
763
822
901
1,006
1,053
1,122
Total Equity
- -
26.25
7.93
10.28
10.83
12.83
13.38
7.98
8.81
12.09
7.3
Return on Invested Capital (%)
- -
79.67
37.67
32.93
29.98
26.97
22
12.46
20.83
17.32
8.74
Return on Capital (%)
- -
85.39
39.42
35.65
30.99
30.79
28.24
18.56
31.51
21.82
11.03
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
43.79%
8.03%
6.48%
Free Cash Flow
-107.7%
-532.02%
-156.66%
Net Income, GAAP
12.01%
14.8%
-41.51%
Sales/Revenue/Turnover
14.27%
10.65%
8.05%
Total Cash Common Dividend
- -
- -
-80.08%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
2,050
2024
- -
- -
- -
- -
2,215
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.19
2024
- -
- -
- -
- -
0.11
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.14
2024
- -
- -
- -
- -
0.03
2025
- -
- -
- -
- -
- -
Similar Companies
Mercury Biopharmaceutical Corporation (6932.TWO)
Swedish Orphan Biovitrum AB (publ) (BIOVF)
RIV Capital Inc. (RIV.TO)
HUTCHMED (China) Limited (0013.HK)
Green Thumb Industries Inc. (GTII.CN)
Aarti Pharmalabs Limited (AARTIPHARM.BO)
Business
Zhongzhi Pharmaceutical Holdings Limited is an investment holding company engaged in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company operates through two main segments, Pharmaceutical Manufacturing and Operation of Chain Pharmacies; it produces and sells Chinese patent medicines and decoction pieces under the Zeus (中智), Liumian (六脉), and Caojinghua (草晶华) brand names, including traditional and modern decoction pieces, broken-wall herbal products, healthcare foods, and Chinese herbs, while also providing detection and testing services, property management, pharmaceutical wholesaling, and traditional Chinese medicine services through its chain pharmacies under the Zeus brand. Zhongzhi Pharmaceutical Holdings Limited maintains 45 herbal ecological traceability planting bases, manufactures food and medical devices sourced from suppliers, and targets domestic markets via its subsidiaries such as Zhongshan Hengsheng Pharmaceutical, Guangdong Yunzhi Chinese Medicine Pieces, and Guangdong Caijinghua Broken-Wall Herbal; founded in 1993, the company is headquartered at No. 3 Kangtai Road South, Torch Development Zone, Zhongshan, Guangdong, and lists as a subsidiary of Crystal Talent Investment Group Limited on the Hong Kong Stock Exchange (3737.HK). In 2024, the company continues to expand its traditional Chinese medicine decoction pieces business under the core Caojinghua brand; insiders, including Chairman Lai Zhi Tian, conducted share acquisitions in April 2024 at prices around HK$0.15-0.16 per share to bolster ownership.